Logo

Danish Government Awards $1.6M to MicroRNA Research Consortium

May 01, 2006

NEW YORK, May 1 (GenomeWeb News) - Danish drug developer Santaris Pharma said today that it has created a MicroRNA Research Consortium in partnership with the Department for Medical Biochemistry and Genetics at the University of Copenhagen.

 

The new consortium is partially supported by a €1.3 million ($1.6 million) grant from the the Danish Advanced Technology Foundation. This will be matched by an additional €1.3 million from the University of Copenhagen and Santaris Pharma.

 

The consortium's first goal will be "to target microRNAs involved in human cancer and develop effective drugs that block their action," Santaris said.

 

The University will have the first right to patent new drug targets discovered in the partnership and Santaris will be responsible for the development and commercialization of antagonists of these targets as potential new cancer drugs.

Breaking News
The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.